Detail akcie Oxford Biomedica Rg online

Business Summary: Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Oxford BioMedica plc revenues decreased 36% to L89.5M. Net loss increased from L39.2M to L157.5M. Revenues reflect United Kingdom segment decrease of 92% to L4M, Europe segment decrease of 29% to L19.8M, Rest of world segment decrease from L396K to L0K. Higher net loss reflects Platform segment loss increase from L17.9M to L174.9M.